GeneTex
United States (US)

p70 S6K (Active) recombinant protein

Cat No. GTX65233

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

132 nmol phosphate incorporated into S6K substrate peptide per minute per mg protein at 30ºC for 15 minutes using a final concentration of 50 uM ATP (0.83 uCi/assay).

Calculated MW

76.0 kDa. ( Note )
PROPERTIES

Form

Liquid

Buffer

50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol

Storage

Store at -80ºC. Product is stable for at least 6-12 months.

Concentration

0.1mg/ml(Please refer to the vial label for the specific concentration.)

Antigen Species

Human

Expression System

Baculovirus (Sf9 insect cells)

Purification


Purity was assessed by SDS-PAGE (≥90%) and by HPLC.

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Ribosomal protein S6 kinase beta1, Ribosomal protein S6 kinase beta-1, PS6K, p70

Background

Activation of cell growth leads to the multiple phosphorylation of 40S ribosomal protein S6. The kinase responsible for controlling this event is termed p70S6K (1). Northern blot analysis shows p70S6K to be ubiquitously expressed in human adult tissues. p70S6K is activated by serum stimulation, and the serum-induced activation is inhibited by wortmannin and rapamycin. p70S6k activity undergoes changes in the cell cycle and increases 20-fold in G1 cells released from G0 (2). The kinase is reactivated 10-fold when cells released from a nocodazole-induced metaphase block enter G1 of the next cell cycle. The immunosuppressive agent rapamycin induces inactivation of p70s6k with no effect on other mitogen-activated kinases (3). The principal target of rapamycin-induced p70s6k inactivation is T389 site on p70S6K, which is located in an unusual hydrophobic sequence outside the catalytic domain. Mutation of T389 to alanine ablates kinase activity, whereas mutation to glutamic acid confers constitutive kinase activity and rapamycin resistance. p70S6K activation by growth factor requires phosphorylation by various inputs on multiple sites (4). p70S6K activation requires sequential phosphorylations at proline-directed residues in the putative autoinhibitory pseudosubstrate domain, as well as threonine 389. Threonine 229, a site in the catalytic loop is phosphorylated by phosphoinositide-dependent kinase 1 (PDK-1). Activation of p70S6K requires a phosphoinositide 3-kinase (PI3-K)-dependent signal(s).

Research Area

Package List Price ($)
$ 349